[The optimization of the treatment of epilepsy with carbamazepine in puberty].
A study was made of the pharmacokinetics of carbamazepine (CBZ) in epileptic patients in the pubertal period. In a group of patients with fully controlled fits, the concentrations of CBZ ranged within the mean values of the therapeutic concentration. Meanwhile in a group with an incomplete therapeutic effect and without any effect, the mean dose of CBZ per kg weight was even higher than that in the group with fully controlled fits. The lack of the clinical effect in part of the patients in the pubertal period on the intake of the seemingly high total doses of CBZ is not to be regarded as a cause of refusing to take it. The dose should be raised under pharmacological control.